2021-02-01 Comments Off on Horizon Therapeutics boosts rare-disease portfolio with $3.05 billion Viela Bio buy Horizon Therapeutics boosts rare-disease portfolio with $3.05 billion Viela Bio buy (Reuters) – Horizon Therapeutics plc has agreed to buy Viela Bio Inc for about $3.05 billion as it looks to